This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dostálová, I. Articles by Haluzík, M. Search for Related Content PubMed PubMed Citation Articles by Dostálová, I. Articles by Haluzík, M. Related Collections Neuroendocrinology and Pituitary Female Endocrinology Metabolism

Plasma Concentrations of Fibroblast Growth Factors 19 and 21 in Patients with Anorexia Nervosa

Ivana Dostálová, Petra Kaválková, Denisa Haluzíková, Zdena Lacinová, Milo Mráz, Hana Papeová and Martin Haluzík

Third Department of Medicine (I.D., P.K., D.H., Z.L., M.M., M.H.) and Departments of Sports Medicine (D.H.) and Psychiatry (H.P.), First Faculty of Medicine, Charles University and General University Hospital, 128 00 Prague 2, Czech Republic

Address all correspondence and requests for reprints to: Martin Haluzik, M.D., Ph.D., Third Department of Medicine, First Faculty of Medicine, U Nemocnice 1, 128 00 Prague 2, Czech Republic. E-mail: mhalu{at}lf1.cuni.cz.

Context: Fibroblast growth factor 19 (FGF19) and FGF21 are novel metabolic regulators that improve insulin sensitivity and decrease adiposity in mice. However, little is known about the nutritional regulation of these factors in humans.

Objective: The objective of this study was to measure plasma FGF19 and FGF21 levels in patients with anorexia nervosa (AN) and to explore its relationship with anthropometric and endocrine parameters.

Design: This was a single-center cross-sectional study.

Setting: The study was performed in a university hospital.

Patients: Seventeen untreated women with a restrictive type of AN and 17 healthy women (control group) were included.

Main Outcome Measures: Fasting plasma FGF19 and FGF21, serum insulin, leptin, soluble leptin receptor, adiponectin, resistin, and C-reactive protein were the main outcome measures.

Results: Plasma FGF19 levels did not significantly differ between the groups studied, whereas plasma FGF21 levels were significantly reduced in AN relative to the control group. Plasma FGF21 positively correlated with body mass index and serum leptin and insulin and was inversely related to serum adiponectin in both groups. In contrast, plasma FGF19 was not related to any of parameters studied. Partial realimentation significantly reduced plasma FGF21 levels in AN.

Conclusion: Circulating levels of FGF21 but not FGF19 are strongly related to body weight and serum levels of leptin, adiponectin, and insulin in both anorectic and normal-weight women. We suggest that reduced plasma FGF21 levels could be involved in the pathophysiology of AN or in a complex adaptive response to this disease.

This article has been cited by other articles:

				C. Christodoulides, P. Dyson, D. Sprecher, K. Tsintzas, and F. Karpe Circulating Fibroblast Growth Factor 21 Is Induced by Peroxisome Proliferator-Activated Receptor Agonists But Not Ketosis in Man J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3594 - 3601. [Abstract] [Full Text] [PDF]

				A. O. Chavez, M. Molina-Carrion, M. A. Abdul-Ghani, F. Folli, R. A. DeFronzo, and D. Tripathy Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance Diabetes Care, August 1, 2009; 32(8): 1542 - 1546. [Abstract] [Full Text] [PDF]

				K. Mai, J. Andres, K. Biedasek, J. Weicht, T. Bobbert, M. Sabath, S. Meinus, F. Reinecke, M. Mohlig, M. O. Weickert, et al. Free Fatty Acids Link Metabolism and Regulation of the Insulin-Sensitizing Fibroblast Growth Factor-21 Diabetes, July 1, 2009; 58(7): 1532 - 1538. [Abstract] [Full Text] [PDF]